Search
Ligand Pharmaceuticals Inc
LGNDAdd to Watchlist
295.920USD
+11.010+3.86%
Close 06/25, 16:00（ET）Quotes delayed by 15 min
5.85BMarket Cap
38.56P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+3.86%
5 Days
+12.46%
1 Month
+29.04%
6 Months
+50.11%
Year to Date
+56.51%
1 Year
+150.31%
Key Figures
288.340Open
300.120High
710.99KVolume
38.56P/E TTM
24.10P/E Dynamic
--Dividend TTM
3.60%Turnover Ratio
284.910Prev. Close
288.340Low
163.52MTurnover
LossP/E Static
5.75P/B
0.00%Div Yield TTM
12.60%ROA
247.38052wk High
0.77Volume Ratio
-4.03MNet Profit
19.77MShares
7.6734EPS TTM
1.23Beta
17.13%ROE
98.89052wk Low
4.13%Amplitude
78.02%Gross Margin
5.85BMarket Cap
10.07Reward/Risk
2.06%Risk Rate
TradingKey Stock Score of Ligand Pharmaceuticals Inc
Currency: USD Updated: 2026-06-24Key Insights
Ligand Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 24 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 277.11.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Ligand Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Ligand Pharmaceuticals Inc Highlights
StrengthsRisks
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 104.16% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 268.09M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 37.13, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 20.97M shares, decreasing 2.30% quarter-over-quarter.
Held by Private Capital
Star Investor Private Capital holds 170.46K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.03.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
277.111
Target Price
-0.83%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Ligand Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Ligand Pharmaceuticals Inc Info
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
Ticker SymbolLGND
CompanyLigand Pharmaceuticals Inc
CEODavis (Todd C)
Websitehttps://www.ligand.com/
Related Instruments
+1.16%
+1.66%
+1.48%
+3.67%
+4.05%
+1.27%
+0.40%
+0.44%
-1.05%
-1.48%
+1.05%
+0.75%
+1.55%
+1.14%
-0.20%
0.00%
-0.53%
+0.73%
+4.24%
-0.54%Popular Instruments
52024.700
+53.000 (+0.10%)
29455.000
-339.200 (-1.14%)
7366.800
-43.600 (-0.59%)
15751.000
+214.000 (+1.38%)
71132.000
+175.000 (+0.25%)
6265.800
+37.600 (+0.60%)
71.344
+1.585 (+2.27%)
275.150
-17.930 (-6.12%)
195.740
-3.260 (-1.64%)
4026.150
+27.410 (+0.69%)
FAQs
What is the current price of Ligand Pharmaceuticals Inc (LGND)?
The current price of Ligand Pharmaceuticals Inc (LGND) is 284.91.
What is the symbol of Ligand Pharmaceuticals Inc?
The ticker symbol of Ligand Pharmaceuticals Inc is LGND.
What is the 52-week high of Ligand Pharmaceuticals Inc?
The 52-week high of Ligand Pharmaceuticals Inc is 247.38.
What is the 52-week low of Ligand Pharmaceuticals Inc?
The 52-week low of Ligand Pharmaceuticals Inc is 98.89.
What is the market capitalization of Ligand Pharmaceuticals Inc?
The market capitalization of Ligand Pharmaceuticals Inc is 5.71B.
Is Ligand Pharmaceuticals Inc (LGND) currently rated as Buy, Hold, or Sell?
According to analysts, Ligand Pharmaceuticals Inc (LGND) has an overall rating of Buy, with a price target of 277.11.
What is the Earnings Per Share (EPS TTM) of Ligand Pharmaceuticals Inc (LGND)?
The Earnings Per Share (EPS TTM) of Ligand Pharmaceuticals Inc (LGND) is 6.13.
